- Home
- KORE vs KZIA Comparison
KORE vs KZIA Comparison
Compare KORE & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KORE | KZIA |
|---|---|---|
| Founded | 2003 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 74.4M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | KORE | KZIA |
|---|---|---|
| Price | $4.89 | $7.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $17.67 |
| AVG Volume (30 Days) | 50.4K | ★ 255.5K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $285,408,000.00 | $1,199,108.00 |
| Revenue This Year | $1.26 | N/A |
| Revenue Next Year | $7.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.06 | N/A |
| 52 Week Low | $2.00 | $2.86 |
| 52 Week High | $5.03 | $17.40 |
Technical Indicators
Market Signals| Indicator | KORE | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 59.25 | 47.35 |
| Support Level | $4.54 | $6.85 |
| Resistance Level | $5.03 | $7.69 |
| Average True Range (ATR) | 0.22 | 0.70 |
| MACD | -0.01 | 0.17 |
| Stochastic Oscillator | 81.38 | 82.85 |
Price Performance
Historical ComparisonAbout KORE KORE Group Holdings Inc.
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.